NEWS & COMMENTS

PROHOST    FILTER

                                                   Eye  On

        As reported in the New York Times, we walked a good distance towards understanding the root cause of metastasis – the spread of cancer to many organs in addition to the organ that hosts the primary tumor. Scientists have already discovered genes that enables the micro- circulating cancerous cells to successfully colonize on other organs made of cells that totally differ from their original host organ. This is good news among many other good news our subscribers will find in the next Prohost N-letter.

        In Today’s news, Amylin Pharmaceuticals (AMLN) and Eli Lilly lifted restrictions on their diabetes drug this week after a cartridge shortage forced the two companies to ask doctors to limit the number of patients they start on the regimen. This news is great for two reasons. The first is that the shortage of cartridges, which is a temporary setback that caused a decline in the stock is an indication of how excellent are the drug sales. The second reason for enthusiasm is the ability of the firms to quickly solve the problem.

This is good news for AMLN. 

        In the news also, ARIAD Pharmaceuticals. (ARIA) announced issuance of a U.S. patent covering its novel mTOR inhibitors, including its lead cancer product candidate - AP23573 - and uses of these compounds to treat various cancers and to prevent reblockage at sites of vascular injury following stent-assisted angioplasty. U.S. Patent No. 7,091,213 provides coverage through the year 2023. AP23573 is set to enter a global Phase 3 clinical trial in patients with advanced sarcomas.  

      Ariad’s drugs that target mTOR are overlooked by many analysts who prefer to base their evaluation only on financial reports.

Read More:  ARIAD Announces Issuance of Key Patent Covering Its mTOR Inhibitors and Treatment Methods in Cancer and Restenosis

As Good as the most powerful antibiotic

GENZYME (GENZ): Results from phase 2 trial of Tolevamer, an investigational polymer therapy for patients with Clostridium difficile-associated diarrhea (CDAD), published in the August 15 issue of Clinical Infectious Diseases show promising results equal to the effect of Vancomycin.  Tolevamer is a novel therapy that could be the first non-antibiotic treatment approved for CDAD, a sometimes deadly form of infectious diarrhea caused by the bacterium C. difficile. Tolevamer is designed to bind and remove from the body toxins released by C. difficile that damage the large intestine.  

This is good news

Read More: Results of Phase 2 Study of Tolevamer for C. difficile-Associated Diarrhea Published in Clinical Infectious Diseases

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm